FDA, CMS hold closed-door clinical AI meetings
MASSACHUSETTS, UNITED STATES — The Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) convened a closed-door “clinical artificial intelligence (AI) demo day” with 10 health tech companies at the FDA’s White Oak headquarters on July 8.
According to STAT News, attendees included major tech platforms and clinical AI startups: Anthropic, Counsel Health, Curai, K Health, Microsoft AI, Amazon One Medical, Doctronic, Ellipsis Health, Hippocratic AI, and Welldoc.
Federal regulators seek AI firsthand exposure
Federal officials from both agencies attended to gain direct experience with clinical artificial intelligence (AI) tools as they operate in live deployments today. Participating companies included startups backed by venture firms Andreessen Horowitz and Khosla Ventures, alongside subsidiaries of Microsoft and Amazon.
STAT News reported that the sessions were designed to give officials “firsthand experience with AI doctor technology as it exists today,” with industry participants using the meetings to make the case for specific regulatory standards and Medicare reimbursement terms.
The July 8 meeting gave federal regulators direct exposure to how clinical AI performs in live clinical workflows before formal rulemaking begins. Four companies spoke with STAT News after the event: Counsel Health, K Health, Hippocratic AI, and Ellipsis Health.
White House sprint targets AI standards
The demo day is part of a broader, coordinated push by the White House Office of Science and Technology Policy (OSTP), FDA, and the Office of the National Coordinator for Health Information Technology (ONC) to develop “consensus principles” for clinical AI benchmarking and evaluation. The initiative, a structured one-month “sprint,” runs in two phases: a written phase followed by a formal discussion phase.
CMS’s presence at the July 8 session signals the agency’s intent to define Medicare reimbursement criteria for AI-assisted clinical services, a question with direct financial implications for hospitals and health systems.
The sprint aims to ensure the United States has federal guardrails for clinical AI assessment before commercial adoption outpaces regulatory readiness. Regulatory clarity on payment eligibility will directly affect how hospitals and health systems budget for AI deployment at scale.
As federal agencies finalize these standards, U.S. health systems face a parallel surge in administrative complexity tied to AI implementation: documentation audits, payer reporting requirements, and compliance tracking. Healthcare outsourcing vendors already serve hospitals and physician groups through revenue cycle management (RCM), medical coding, and clinical documentation support.
For health systems managing AI adoption under regulatory uncertainty, outsourcing these functions offers a measurable path to cost containment. Firms in the Philippines and India already handle prior authorization appeals, clinical documentation, and billing verification for providers absorbing AI-generated workflow volume.
Related news
- Medicare’s AI pilot sparks deny-faster fears · 29 Jul
- AI prior authorization faces bipartisan backlash in congress · 25 Jun
- CMS launches office of health technology to drive AI adoption · 17 Jun
Disclosure: Outsource Accelerator uses AI tools in the backend of its editorial workflow. Every article is reviewed and verified by a human editor before publication.
Stay ahead in healthcare outsourcing. Join thousands of healthcare and business leaders who rely on Outsource Accelerator for the news, trends, and expert insights shaping medical BPO and the future of care delivery. Subscribe to our free newsletter and never miss an update.
